Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Setogepram. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 known ✓ | Q9NQS5 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | PPARA | Q07869 | 4/20 | 0.60 |
| ▸ | PPARG | P37231 | 2/20 | 0.60 |
| ▸ | LPL | P06858 | 2/20 | 0.54 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.52 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Setogepram SCHEMBL29395927 | 1.00 | ALDH1A1 (0.69) | ALDH1A1HPGDHSD17B10PPARAPPARG | |
| SCHEMBL28899619 | 0.98 | ALDH1A1 (0.67) | ALDH1A1HPGDHSD17B10PPARAPPARG | |
| Setogepram SCHEMBL19095289 | 0.98 | ALDH1A1 (0.67) | ALDH1A1HPGDHSD17B10PPARAPPARG | |
| Setogepram SCHEMBL19095287 | 0.98 | ALDH1A1 (0.67) | ALDH1A1HPGDHSD17B10PPARAPPARG | |
| SCHEMBL15199282 | 0.98 | ALDH1A1 (0.67) | ALDH1A1HPGDHSD17B10PPARAPPARG | |
| SCHEMBL10963130 | 0.95 | ALDH1A1 (0.68) | ALDH1A1HPGDHSD17B10PPARAPPARG | |
| SCHEMBL15042342 | 0.87 | AKR1B1 (0.54) | ALDH1A1HPGDHSD17B10PPARAPPARG | |
| Setogepram SCHEMBL28166702 | 0.87 | ALDH1A1 (0.57) | ALDH1A1HPGDHSD17B10PPARAPPARG | |
| SCHEMBL2617117 | 0.86 | GPR84 (0.54) | ALDH1A1PPARAPPARGGPR84LPL | |
| SCHEMBL288982 | 0.86 | PPARA (0.60) | ALDH1A1PPARAPPARGLPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3595649-B1 | 5-((2R,4AR,10BR)-9-ETHOXY-2-HYDROXY-8-METHOXY-1,2,3,4,4A,10B-HEXAHYDRO-PHENANTHRIDIN-6-YL)1-METHYL-1H-PYRIDIN-2-ONE FOR USE IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | TAKEDA PHARMACEUTICALS CO (JP) | 2025-10-01 | — | — | EP | claimed |
| US-11690839-B2 | Treatment of idiopathic pulmonary fibrosis | TAKEDA GMBH (DE) | 2023-07-04 | — | — | US | claimed |
| CN-116102423-A | Method for preparing (3-pentylphenyl) acetic acid | 济南明微医药科技有限公司 | 2023-05-12 | — | — | CN | claimed |
| US-20220016060-A1 | USE OF SODIUM 2-(3-PENTYLPHENYL)ACETATE IN THE TREATMENT OF ALSTRÖM SYNDROME | Liminal Biosciences Limited (GB) | 2022-01-20 | — | — | US | claimed |
| EP-3890717-A1 | USE OF SODIUM 2-(3-PENTYLPHENYL)ACETATE IN THE TREATMENT OF ALSTRÖM SYNDROME | Liminal Biosciences Limited (GB) | 2021-10-13 | — | — | EP | claimed |
| US-20210113549-A1 | TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-22 | — | — | US | claimed |
| WO-2020113340-A1 | USE OF SODIUM 2-(3-PENTYLPHENYL)ACETATE IN THE TREATMENT OF ALSTRÖM SYNDROME | Liminal Biosciences Limited (GB) | 2020-06-11 | — | — | WO | claimed |
| CN-110573148-A | treatment of idiopathic pulmonary fibrosis | 武田有限公司 | 2019-12-13 | — | — | CN | claimed |
| WO-2018167142-A1 | TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | TAKEDA GMBH (DE) | 2018-09-20 | — | — | WO | claimed |
| US-8637574-B2 | Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof | PROMETIC BIOSCIENCES, INC. (CA) | 2014-01-28 | — | — | US | claimed |
| EP-2427417-B1 | SALTS OF 3-PENTYLPHENYLACETIC ACID AND PHARMACEUTICAL USES THEREOF | PROMETIC BIOSCIENCES INC (CA) | 2013-10-09 | — | — | EP | claimed |
| US-20120095102-A1 | Salts of 3-Pentylphenylacetic Acid and Pharmaceutical Uses Thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2012-04-19 | — | — | US | claimed |
| EP-2427417-A1 | SALTS OF 3-PENTYLPHENYLACETIC ACID AND PHARMACEUTICAL USES THEREOF | ProMetic BioSciences Inc. (CA) | 2012-03-14 | — | — | EP | claimed |
| WO-2010127448-A1 | SALTS OF 3-PENTYLPHENYLACETIC ACID AND PHARMACEUTICAL USES THEREOF | PROMETIC BIOSCIENCES INC. (CA) | 2010-11-11 | — | — | WO | claimed |
| EP-4200297-B1 | IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4200015-B1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL MYERS SQUIBB CO (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12590091-B2 | 1H-pyrrolo[3,2-C]pyridine and 1H-pyrrolo[2,3-C]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-03-31 | — | — | US | disclosed |
| US-6552067-B2 | For therapy of osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis | PFIZER INC. | 2003-04-22 | — | — | US | disclosed |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | LOTUS PHARMACEUTICAL CO., LTD. (JP) | 2002-05-30 | — | — | US | disclosed |
| WO-2002042268-A2 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590091-B2 | 1H-pyrrolo[3,2-C]pyridine and 1H-pyrrolo[2,3-C]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis | TLR9, TLR1, TLR3 | GPR84 294/4885ALDH1A1 3124/4885HPGD 4153/4885 |
| US-20120095102-A1 | Salts of 3-Pentylphenylacetic Acid and Pharmaceutical Uses Thereof | GLS, REN, PTP4A3 | GPR84 2727/4885ALDH1A1 144/4885HPGD 838/4885 |
| US-20220016060-A1 | USE OF SODIUM 2-(3-PENTYLPHENYL)ACETATE IN THE TREATMENT OF ALSTRÖM SYNDROME | TNNT2, CPT1B, TNNC1 | GPR84 4270/4885ALDH1A1 1471/4885HPGD 3820/4885 |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | GPR84 39/4885ALDH1A1 2541/4885HPGD 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.